Medical Doctor Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Shreeya Popat

Urology Houston, TX Medical Doctor

NPI 1215399340 CMS profile 11311281

1 Baylor Plz, Suite 404D, Houston, TX 77030

Open in the dashboard

General payments

$5,729

66 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Shreeya Popat of Houston, TX is reported in the CMS Open Payments database as having received $5,729 across 66 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 68th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $150 3
2024 General $607 10
2023 General $3,003 35
2022 General $577 6
2021 General $1,392 12

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Shreeya Popat
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Shreeya Popat were reported at $150. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Shreeya Popat Urology median Middle half National median
2019 $0 $480 $147–$1,201 $163
2020 $0 $246 $87–$645 $114
2021 $1,392 $358 $111–$1,000 $132
2022 $577 $476 $143–$1,263 $149
2023 $3,003 $560 $168–$1,461 $160
2024 $607 $563 $170–$1,464 $164
2025 $150 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Boston Scientific Corporation $3,036 30 payments
  2. Medtronic, Inc. $1,631 23 payments
  3. Valencia Technologies Corporation $426 2 payments
  4. Progenics Pharmaceuticals, Inc. $151 1 payment
  5. C. R. Bard, Inc. & Subsidiaries $129 5 payments
  6. CooperSurgical, Inc. $118 1 payment
  7. Innovation Technologies Inc $107 1 payment
  8. Bayer HealthCare Pharmaceuticals Inc. $57 1 payment
  9. Coloplast Corp $47 1 payment
  10. Sumitomo Pharma America, Inc. $27 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $3,444 50 payments
  2. Travel and Lodging $2,194 15 payments
  3. Education $91 1 payment
Products named General payments · program years 2021–2025
  1. INTERSTIM $1,631 23 payments
  2. GENERAL PAIN MANAGEMENT $1,284 10 payments
  3. Solyx SIS System $607 7 payments
  4. eCoin Device Kit $426 2 payments
  5. PYLARIFY $151 1 payment
  6. AMS 700 $133 2 payments
  7. ALLY II UPS $118 1 payment
  8. General Erectile Dysfunction $108 2 payments
  9. Irrisept $107 1 payment
  10. Bard Urinary Drainage Bag $75 2 payments
  11. Other $235 6 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

762

Median for Urology: 1,053

Drug cost

$152,003

Median for Urology: $101,464

Branded share of claims

65.6%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gemtesa Vibegron Brand 175 $120,965
Trospium Chloride Er Trospium Chloride Brand 56 $8,332
Estradiol Generic 122 $7,832
Myrbetriq Mirabegron Brand 18 $7,696
Tamsulosin Hcl Generic 89 $3,344
Oxybutynin Chloride Er Oxybutynin Chloride Brand 54 $2,531
Finasteride Generic 12 $528
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 38 $322
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 102 $142
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 23 $133

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Records

66 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record